Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Q2 2022 Earnings Presentation
16 slides from Bioporto A/s's earnings presentation, Aug 17, 2022
Slide 1: Empowering Early Detection of Kidney Injury
Empowering Early Detection of Kidney Injury 2022-Q2 Earnings Call August 17, 2022 © Copyright BioPorto | 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Highlights from Q2 2022
Highlights from Q2 2022 • Strong financial performance – revenue up 29% YoY in Q2 and 23% YoY in 1H 2022 • Targeted enrollment of patients for US FDA application of The NGAL Test achieved • Appointment of Dr. Devarajan as new Senior Medical Director © Copyright BioPorto | 3
Slide 4: We save lives and improve quality of life with actionable biomarkers
We save lives and improve quality of life with actionable biomarkers In 2022-2023 we will Launch an FDA Cleared Product in the US Drive Market Adoption of the NGAL Test & have a Pipeline of Products that Deliver High Medical Value Strengthen the Company to Scale & Execute Attract, Develop & Retain t
Slide 5: AKI represents a $24B burden on US healthcare
AKI represents a $24B burden on US healthcare1 Highly Prevalent & Costs up to $27,300/patient1 AKI Correlates with Higher Mortality10 1 in 5 ADULTS 2 & 1 in 4 CHILDREN3 25,5% Is affected with AKI during hospitalization Cardiac Surgery 4 30% 16,9% Sepsis5 50% 12,6% ~15X Nephrotoxic Medication 6 14-26
Slide 6: Current method, Serum Creatinine (sCr), is delayed and non-specific
Current method, Serum Creatinine (sCr), is delayed and non-specific In a multicenter prospective study of over 500 biopsy-diagnosed cases of moderate to severe AKI, sCr only properly identified 26% of patients1 Delayed and Dampened Non-specific for AKI Confounded by Other Factors Does not rise until
Slide 7: Benefit of The NGAL Test's NPV – Case Study: Avoiding Dialysis
Benefit of The NGAL Test’s NPV – Case Study: Avoiding Dialysis NGAL closely follows AKI progression vs. sCr lags, is slow, and is non-specific NGAL ng/ml sCr mg/dl A Patient had a significant discordance 400 9,0 between sCr and NGAL starting on Day 2 NGAL sCr 350 8,0 7,0 300 A 6,0 250 5,0 200 B 4,0
Slide 8: NGAL results guides preventative and restorative care pathways
NGAL results guides preventative and restorative care pathways Near real time information can make the difference The NGAL Test can make the difference in Serum creatinine The NGAL Test informing: detected 48-72 hours detected 2-3 hours post-injury • Nephrotoxic medications or dosing adjustments • F
Slide 9: FDA Granted "Breakthrough Device Designation"
FDA Granted “Breakthrough Device Designation” The Breakthrough Devices Program provides prioritized FDA review Eligibility Criteria1: • “provides for more effective treatment or diagnosis of life- threatening or irreversibly debilitating human disease or conditions” • Satisfies one of the following:
Slide 10: On track for a 2022 FDA De Novo submission
On track for a 2022 FDA De Novo submission Complete last Commercial FDA Approval of Data FDA US clinical study Preparedness NGAL in ICU for analysis submission Launch enrollment Execution up to age 22 1 Next steps after FDA submission – Focused on Age 22+: • Conduct Scientific Advisory Board to prio
Slide 11: BioPorto grew revenue by 29% in Second Quarter 2022
BioPorto grew revenue by 29% in Second Quarter 2022 Revenue by Quarter YTD Revenue by Product Group 2021 NGAL Tests Antibodies Others 2022 8,5 7,1 6,9 6,8 6,5 6,6 5,9 5,4 5,6 Q2 5,3 Q2 Q2 Q2 Q1 Q1 0,9 1,1 Q1 Q1 Q1 Q1 Q2 Q3 Q4 2021 2022 2021 2022 2021 2022 amounts in DKKm © Copyright BioPorto | 11
Slide 12: Continued growth in The NGAL Test sales
Continued growth in The NGAL Test sales The NGAL Test sales by Quarter (LTM, DKKm) US NGAL 31% NGAL Increase in total revenue from 13,7 14,1 +68% 13,4 13,5 12,1 12,0 12,1 13,6 13,2 US NGAL sales from 1H 2021 to 1H 2022 11,3 10,5 Global NGAL 19% 9,6 9,4 9,5 Development in global sales of NGAL from 1H
Slide 13: Solid cash position and continued working capital management
Solid cash position and continued working capital management Adj. EBITDA and cash position (DKKm) Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 • H1’22 cash burn from operations: DKKm 28.4, Adj. EBITDA 107,9 a 20% reduction vs. H1’21 Cash position • Cash balance: DKKm 107.9 75,0 59,6 45,4 27,0 -14,5 -15,0
Slide 14: Guidance for 2022 & Q2 Cash Position
Guidance for 2022 & Q2 Cash Position Amounts in millions of Danish Kroner and US Dollars1 Actual at Guidance June. 30, 2022 EBIT loss Revenue Cash2 Adj. EBITDA loss DKK 24-27 DKK 95-100 DKK 76-81 DKK 108 $3.3-3.8 $13.3-14.0 $10.6-11.3 $15.1 1All Financial Figures Converted from DKK to USD at a rate
Slide 15: Investment Thesis: The first meaningful Acute Kidney Injury (AKI) test
Investment Thesis: The first meaningful Acute Kidney Injury (AKI) test Clinicians are demanding and using The NGAL Test - a better kidney injury diagnostic The NGAL Test saves kidneys & lives with AKI detection when the injury is clinically silent Serves a $3B+ global Market Opportunity in AKI as a
Slide 16: Investor Relations Contacts
Investor Relations Contacts CPH:BIOPOR EU: Tim Eriksen US: Ashley Robinson Managing Partner Managing Director Zenith Advisory LifeSci Advisors investor@bioporto.com arr@lifesciadvisors.com +45 4529 0000 +1 617 430 7577 © Copyright BioPorto | 16